04/10/2022at 11:49

EFPIA calls for US-like voucher system to boost European antibiotic research

The pharmaceutical association says the priority review voucher in the US could be the way forward in Europe to nudge companies to research and develop new antibiotics.

Photo: Monika Skolimowska/AP/Ritzau Scanpix

by christian bundgaard, translated by daniel pedersen

European antimicrobial research and development needs a boost, and the implementation of a system like the priory review voucher in the US could be what gets the ball rolling, reports media Endpoints News citing research funded by the European Federation of Pharmaceutical Industries and Associations, EFPIA.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

EMA publishes new plan to support antibiotic development
For subscribers
Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance
For subscribers
Drugmakers aim to curb release of antibiotic waste into the environment
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

EU weighs plan to incentivize drugmakers to fight superbugs

A Netflix-style subscription model following the UK’s example could incentivize antibiotic making to curb to the increasingly gloomy prospects of drug-resistant infections.

For subscribers